![Page 1: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/1.jpg)
chapter 15microbial mechanisms of
pathogenicity
![Page 2: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/2.jpg)
pathogenesis
![Page 3: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/3.jpg)
portals of entry & exit
![Page 4: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/4.jpg)
inoculation vs. disease: preferred portal of entryentry DOES NOT EQUAL disease
entry into preferred portal of entry DOES NOT EQUAL disease
ID50: infectious dose for 50% of population
– inhalation anthrax: <104 spores
– V. cholerae: 108 cellsLD50 : lethal dose for 50%
– botulinum toxin: 0.03 ng/kg
– E. coli shiga toxin: 250 ng/kg
![Page 5: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/5.jpg)
pathogenesis: enzymes
coagulase & kinase
hyaluronidase&
collagenase
leukocidins
![Page 6: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/6.jpg)
toxicity: bacterial toxins
exotoxin endotoxin
source Gram positive/enterics Gram negative
expressed gene outer membrane component
chemical make-up protein lipid
neutralized by antitoxin? yes no
fever? no yes
LD50 (relative) small large
allow spread and cause damage to the host• toxigenicity: ability to produce a toxin• toxemia: toxin in blood• toxoid: immunization• antitoxin: Ab to toxin
![Page 7: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/7.jpg)
cytotoxins: hemolysins
![Page 8: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/8.jpg)
neurotoxins: Clostridium
![Page 9: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/9.jpg)
enterotoxins: V. cholerae
![Page 10: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/10.jpg)
endotoxins: fever
![Page 11: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/11.jpg)
Salmonella virulence
![Page 12: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/12.jpg)
mechanisms of pathogenicity
Inactivating host defenses
![Page 13: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/13.jpg)
chapter 15 learning objectives1. Describe pathogenesis from exposure to disease. What factors contribute to disease?
2. Relate preferred portal of entry and ID50 to the likelihood of infection.
3. Know how to interpret ID50 and LD50 results.
4. Describe what is meant by invasiveness and the mechanisms and factors that affect invasiveness
(adherence, penetration, avoidance of phagocytosis, ability to cause damage).
5. Be able to list enzymes produced by microbes than enhance pathogenicity and virulence as well as
describe the effects of these enzymes on the host (i.e., hyaluronidase, collangenase, coagulase,
kinase).
6. Differentiate between an endotoxin and an exotoxin as far as source, chemistry and type of
molecule (protein, or polysaccharide/lipid). List and understand how examples from class work (e.g.,
cytotoxin, hemolysin, neurotoxin, enterotoxin, endotoxin). It is not necessary to know the particular
details of how each of the three types of exotoxins work.
STUDY ANIMATION URLs
endotoxin production
virulence factors animation
exotoxin production
penetrating host tissues
inactivating/avoiding the host defenses (just for your information)
avoiding host defenses (just for your information)
![Page 14: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/14.jpg)
chapter 20antimicrobial compounds
![Page 15: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/15.jpg)
chemotherapeutic agentsPaul Ehrlich- 1910’s • salvarsan (synthetic arsenic)
to treat syphilis
Alexander Fleming- 1928• Penicillium notatum
Howard Florey- 1940• P. notatum effectivity
![Page 16: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/16.jpg)
antimicrobialsinhibition of protein synthesis: chloramphenicol, erythryomycin, tetracyclines, streptomycin
Transcription Translation
ReplicationEnzyme
ProteinDNA mRNA
inhibition of NA replication & Xscription: quinolones, rifampin
inhibition of cell wall synthesis: penicillins, cephalosporins, bacitracin, vancomycin
injury to plasma membrane: polymyxin B
inhibition of metabolite synthesis: sulfanimide, trimethoprim
![Page 17: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/17.jpg)
protein synthesis inhibition
Translation
Streptomycin Tetracyclines
Chloramphenicol
Messenger RNA
Direction of ribosome movement
70S prokaryotic ribosome
tRNA
Protein synthesis site
30S portion
50S portion
Changes shape of 30S portion, causing code on mRNA to be read incorrectly
Interfere with attachment of tRNA to mRNA–ribosome complex
Binds to 50S portion and inhibits formation of peptide bond
![Page 18: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/18.jpg)
GFA: metabolite inhibition & synergism
![Page 19: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/19.jpg)
Phosphate
Nucleoside
Guaninenucleotide
Cellularthymidine kinase
DNA polymeraseIncorporated into DNA
Phosphate
DNA polymerase blocked by false nucleotide. Assembly of DNA stops.
False nucleotide(acyclovir triphosphate)
Acyclovir (resembles nucleoside)
ViralThymidine kinase
GFAs: nucleic acid inhibition
![Page 20: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/20.jpg)
penicillin & cell wall synthesis inhibitionCELL WALL FORMATION
autolysins cut wall
new “bricks” inserted
transpeptidase bonds bricks
PENICILLIN ACTION
transpeptidase binds pen.
forms PBP-antibiotic structure
no new bond
formation
cell ruptures
![Page 21: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/21.jpg)
Abx resistance
1. outdated, weakened, inappropriateAbx use
2. use of Abx in animal feed
3. long-term, low-dose Abx use
4. aerosolized Abx in hospitals
5. failure to follow prescribed treatment
![Page 22: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/22.jpg)
the episilometer (E) test- the MIC
![Page 23: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/23.jpg)
Abx resistance1. loss of porins
- Abx/drug movement into cell
2. Abx modifying enzymes
-cleave β-lactam ring
-Anx non-functional
3. efflux pumps
- movement out of cell
4. target site mutations
-enzymes
-polymerases
-ribosomes
-LPS layer
Resistance mechanisms
![Page 24: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/24.jpg)
the effect of -lactamase on -lactam Abx
VERY STABLE RESISTANCE• NDM-1 (metallo- -lactamase)
• K. pneumoniae & E. coli, plasmids & chromosomal
• KPC (K. pneumoniae carbapenemase, class of -lactamase)
RESISTANCE RESISTED• clavulinic acid/sulbactam bind -
lactamase• can be hydrolyzed by high
copy # plasmid -lactamase
![Page 25: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/25.jpg)
-lactamsNarrow-spectrum• β-lactamase sensitive
benzathine penicillinbenzylpenicillin (penicillin G)phenoxymethylpenicillin
(penicillin V)procaine penicillin
• Penicillinase-resistant penicillins methicillin, oxacillinnafcillin, cloxacillindicloxacillin, flucloxacillin
• β-lactamase-resistant penicillins temocillin
Moderate-spectrumamoxicillin, ampicillin
Broad-spectrumco-amoxiclav
(amoxicillin+clavulanic acid)Extended-spectrum
azlocillin, carbenicillinticarcillin, mezlocillin, piperacillin
Cephalosporins • 1st generation: moderate
cephalexin, cephalothincefazolin
• 2nd generation: moderate, anti-Haemophiluscefaclor, cefuroxime, cefamandole
• 2nd generation cephamycins: moderate, anti-anaerobecefotetan, cefoxitin
• 3rd generation: broad spectrumceftriaxone, cefotaximecefpodoxime, cefiximeceftazidime (anti-Pseudomonas activity)
• 4th generation: broad, anti-G+ & β-lactamase stabilitycefepime, cefpirome
• Carbapenems and Penems: broadest spectrumimipenem (with cilastatin), meropenemertapenem, faropenem, doripenem
• Monobactamsaztreonam (Azactam), tigemonamnocardicin A, tabtoxinine-β-lactam
![Page 26: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/26.jpg)
bacterial resistance
2009 CASE STUDY, U. of Pittsburgh Medical Center
• 6/2008- post-surgical hospitalization, septicemia (E. coli & E. cloacae)
• 7/2008- UTI, E. coli & P. mirabilis
• 8/2008- UTI, E. coli (imipenem S) & K. pneumoniae (imipenem R & ertapenem R)
• 9/2008- abdominal tissue infection, E. coli & K. pneumoniae (both R to Abx)
• 11/2008- sputum P. aeruginosa & S. marcescens, K. pneumoniae
• 12/2008- MDR-pneumonia, A. baumanii & M. morganii
• 1/2009- sputum, S. marcescens (ertapenem & imipenem R)
![Page 27: Chapter 15 microbial mechanisms of pathogenicity](https://reader036.vdocuments.us/reader036/viewer/2022081506/56649cdc5503460f949a6bd7/html5/thumbnails/27.jpg)
chapter 20learning objectives1. What is the major difference between an antibiotic and a drug? What were the first drug and antibiotic?
2. Antimicrobial agents target which areas of the bacterial cell? How specifically do antibiotics inhibit protein
synthesis?
3. Describe the mechanism of action of penicillin on the bacterial cell.
4. List and explain the effects of antibiotic/drug action on the bacterial cell and the action of penicillin
specifically.
5. Discuss the mode of action of growth factor analogs in general and sulfa drugs and acyclovir specifically.
6. How are antibiotic use and antibiotic resistance related? How are antibiotics abused?
7. Define bacteriolytic, bacteriostatic, bactericidal, MIC, MBC. Describe how MIC is calculated and what it will
tell you about a given bacterium.
8. Understand the four major ways that antibiotic resistance is achieved. Include -lactamases and
clavulanate/clavulinic acid specifically.
STUDY ANIMATION URLs
mechanisms of Abx resistance
the origins of Abx resistance
the emergence of Abx resistance
cell wall formation, ß-lactam ABx and resistance